anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12345678910111213...4142»
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date:  Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) -  Oct 15, 2024   
    P4,  N=137, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Mar 2030 --> Feb 2028 | Trial primary completion date: Feb 2030 --> Jan 2028
  • ||||||||||  anastrozole / Generic mfg.
    Licorice: Treat or Poison? () -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5181;    
    64 year old woman with diagnosis of stage 1B HR+ Her2- Left breast IDC, DCIS s/p lumpectomy, completed adjuvant radiation 6 months ago who was recommended by onclology to take anastrozole for 5 years as adjuvant therapy which she refused and instead saw a Chinese traditional practitioner and was started on supplements that included licorice 6 grams/day...Glycyrrhizic acid onsumption in excess of 100 to 200 mg daily has been noted to cause clinically significant complications.In addition to electrolyte abnormalities, licorice induced HTN and hypertensive encephalopathy, hypokalemic myopathy manifesting as flaccid paralysis, and QT prolongation and possible torsade de pointes with fatal arrhythmias can be seen.Our patient was asymptomatic ,which in fact put her at higher risk of cardiac complications and sudden death given her prolonged QT findings. Presenting to the ED with non related flank pain potentially saved her life..
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change:  CardioVOLT: Cardiovascular Outcomes of Low Testosterone (clinicaltrials.gov) -  Oct 9, 2024   
    P=N/A,  N=232, Completed, 
    Trial completion date: Jul 2030 --> Oct 2030 Active, not recruiting --> Completed | N=379 --> 232
  • ||||||||||  Review, Journal:  New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (Pubmed Central) -  Sep 30, 2024   
    Conversely, udenafil, racecadotril, sotatercept, anastrozole, riociguat, tacrolimus, and ralinepag were found to be safe, well-tolerated, and effective in improving hemodynamic measures and 6-MWDs. This study aims to summarize the developing treatment options currently under clinical trials, highlighting the need for further trials before their application in clinical practice.
  • ||||||||||  anastrozole / Generic mfg.
    Preclinical, Journal:  Supraphysiological Dose of Testosterone Impairs the Expression and Distribution of Sex Steroid Receptors during Endometrial Receptivity Development in Female Sprague-Dawley Rats. (Pubmed Central) -  Sep 29, 2024   
    In this study, adult female Sprague-Dawley rats (n = 24) were subcutaneously administered 1 mg/kg/day of testosterone alone or in combination with the inhibitors (finasteride or anastrozole or both) from day 1 to day 3 post-coitus, while a group of six untreated rats served as a control group...This study shows that a supraphysiological dose of testosterone was able to interrupt the short period of the implantation window. This finding could serve as a basis for understanding the role of testosterone in endometrial receptivity in order to develop further therapeutic approaches targeting androgen-mediated disorders of endometrial receptivity.
  • ||||||||||  Let's Break It Down! A Case of Hypokalemia-Induced Rhabdomyolysis (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_1421;    
    She was on the lowest dose of Atorvastatin, which has a dose-dependent risk of myotoxicity. Anastrozole and Omeprazole are CYP3A4 inhibitors, however, her Anastrozole dose was reduced and Omeprazole is a weak inhibitor.
  • ||||||||||  Apristor (onapristone XR) / Context Therap
    Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Pan tumor:  A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone (clinicaltrials.gov) -  Sep 20, 2024   
    P2,  N=34, Completed, 
    Anastrozole and Omeprazole are CYP3A4 inhibitors, however, her Anastrozole dose was reduced and Omeprazole is a weak inhibitor. Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Sep 2024 | Trial primary completion date: Apr 2025 --> Sep 2024
  • ||||||||||  Journal, Adverse events:  Risk of ocular adverse events with aromatase inhibitors. (Pubmed Central) -  Sep 19, 2024   
    Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.
  • ||||||||||  bireociclib (XZP 3287) / Sihuan Pharmaceutical
    Enrollment closed, Enrollment change, Trial completion date:  A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (clinicaltrials.gov) -  Sep 19, 2024   
    P1/2,  N=402, Active, not recruiting, 
    This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities. Recruiting --> Active, not recruiting | N=300 --> 402 | Trial completion date: Dec 2022 --> Dec 2025
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Ethnicity assessment of ribociclib pharmacokinetics in advanced breast cancer patients (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_413;    
    In addition, at 400 mg dose, PK exposure (AUC, C max and/or C trough ) in Japanese patients was comparable to non-Japanese Asian patients (A2115) and global patients (the sample size in A2115 was small). Conclusions Considering ribociclib PK variability and inter-study variabilities, PK exposure of ribociclib were largely comparable between Caucasian and Asian patients with aBC.
  • ||||||||||  LOXO-783 / Eli Lilly
    Enrollment closed, Enrollment change, Combination therapy, Monotherapy, Metastases:  PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) -  Sep 4, 2024   
    P1,  N=193, Active, not recruiting, 
    ClinicalTrials.gov identifier: NCT03481998. Recruiting --> Active, not recruiting | N=400 --> 193
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Journal, Adverse events:  Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. (Pubmed Central) -  Aug 31, 2024   
    Additionally, letrozole was also associated with lots of other rare but serious AEs in hematologic, respiratory, and hepatic systems, which were not recorded in the instructions. Our analysis of safety warning signals of the third-generation AIs from the FAERS database provided reference for clinical safe and rational drug use.
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov) -  Aug 22, 2024   
    P2,  N=201, Completed, 
    Our analysis of safety warning signals of the third-generation AIs from the FAERS database provided reference for clinical safe and rational drug use. Active, not recruiting --> Completed
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    Trastuzumab-Induced Hepatotoxicity and Outcomes (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5313;    
    The liver injury associated with trastuzumab is usually self-limited as it is not associated with other symptoms such as jaundice, but the hepatotoxicity from ado-trastuzumab emtansine is often fatal; there have also been findings non-cirrhotic portal hypertension on EGD. Figure: Figure 1: Minimal Periportal fibrosis without cholestatic changes Figure 2: Passive sinusoidal congestion
  • ||||||||||  anastrozole / Generic mfg.
    The Gut Feeling: Unraveling the Quest for the Origin of Tumor Marker (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_4631;    
    She declined adjuvant chemotherapy, radiation therapy and started anastrozole 1mg daily...This proactive approach promotes prompt detection and management of potential GI metastasis, improving patient outcomes. Figure: Figure 1, MRI abdomen W WO contrast revealing a 3 x 2.5 cm lobulated cyst at the junction of right and left liver lobes.
  • ||||||||||  anastrozole / Generic mfg.
    An Unfortunate Case of Breast Cancer Metastasis to the Stomach (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3906;    
    Case Description/ A 59-year-old female with right lobular carcinoma diagnosed in 2020, post bilateral mastectomy, chemotherapy, radiation, on Anastrozole, presented with abdominal distention, dyspnea on exertion, pedal edema for three weeks...Timely endoscopic evaluation and proper diagnosis aid in proper treatment. Figure: Gastric Body
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Truqap (capivasertib) / Otsuka, AstraZeneca
    An Uncommon Case of Metastatic Breast Cancer to the Esophagus Causing Pseudoachalasia (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_1031;    
    Case Description/ A A 65-year-old female with recurrent ER/PR+ stage II (T2N0) breast cancer on anastrozole and palbociclib presented with dysphagia to solids and liquids along with nausea and vomiting...The patient subsequently received palliative esophageal radiation therapy along with initiation of capivasertib and fulvestrant...Figure: EUS notable for circumferential esophageal wall thickening to 7mm. Enlarged lymph node at 25 cm from incisors (red arrow) measured at 18.6 x 6.6mm status post fine needle biopsy
  • ||||||||||  Eligard (leuprolide acetate) / Tolmar, Sanofi
    Trial completion date, Trial primary completion date, Combination therapy:  OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov) -  Aug 9, 2024   
    P3,  N=250, Recruiting, 
    Toxicity, health-related quality of life, and circulating biomarkers predicting early NET response will also be evaluated. Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026